Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Drug

Lepu Medical Wins NMPA Approval for Polylactic Acid Facial Filler

Fineline Cube Jun 4, 2025

Beijing-based Lepu Medical Technology (SHE: 300003), a provider of cardiovascular disease solutions, announced that its...

Company Drug

JNJ Reveals Positive AMPLITUDE Phase III Results for Akeega in mHSPC at ASCO 2025

Fineline Cube Jun 4, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced initial results from the Phase III...

Company Drug

Hansoh Pharma’s Almonertinib Approved in UK for EGFR-Mutated NSCLC

Fineline Cube Jun 4, 2025

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved China-based Hansoh Pharmaceutical Group...

Company Medical Device Policy / Regulatory

EU Bars Chinese Medical Device Makers from Public Tenders Over €5M for Five Years

Fineline Cube Jun 4, 2025

China Central Television (CCTV) reported that EU member states have voted under the International Procurement...

Company Drug

Legend Biotech Presents 5-Year Carvykti Data at ASCO 2025

Fineline Cube Jun 4, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) presented 5-year follow-up data from the CARTITUDE-1 study for...

Company Drug

EU Approves Pfizer and Takeda’s Adcetris in Hodgkin Lymphoma Combination Regimen

Fineline Cube Jun 4, 2025

Partners Pfizer (NYSE: PFE) and Takeda (TYO: 4502) announced that the European Commission (EC) has...

Company Drug

Biokin Pharma Enrolls First Patient in BL-M07D1 Phase III Trial for HER2 Low Breast Cancer

Fineline Cube Jun 3, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced the enrollment of the first patient...

Company Deals

Sanofi to Acquire Blueprint Medicines for $9.1 Billion to Expand Rare Disease Pipeline

Fineline Cube Jun 3, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) announced plans to acquire US-based Blueprint Medicines Corporation for...

Company Deals

BioNTech Partners with BMS to Jointly Develop BNT327 for Solid Tumors

Fineline Cube Jun 3, 2025

Germany-based BioNTech SE (NASDAQ: BNTX) announced a strategic partnership with US major Bristol-Myers Squibb (BMS,...

Company Deals Drug

Harbin Pharma Agrees to Acquire Clinical Approval for Jesduvroq from Bocimed

Fineline Cube Jun 3, 2025

China’s Harbin Pharmaceutical Group Holding Co., Ltd (SHA: 600664) announced a technology transfer agreement with...

Company Drug

Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025

Fineline Cube Jun 3, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) presented clinical updates for its investigational drugs...

Company Drug

Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting

Fineline Cube Jun 3, 2025

Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for HRS9531 Clinical Study in Type 2 Diabetes

Fineline Cube Jun 3, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...

Company Drug

Huadong Medicine Files for NMPA Approval of Ranibizumab Biosimilar

Fineline Cube Jun 3, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market approval filing for a...

Company Deals

Hansoh Pharmaceutical Partners with Regeneron for HS-20094 Global Rights

Fineline Cube Jun 3, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with Regeneron Pharmaceuticals...

Company Drug

CSPC Pharmaceutical’s JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer

Fineline Cube Jun 3, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its JMT101 has been awarded breakthrough...

Company Drug

Zai Lab Presents ZL-1310 Clinical Results for Small Cell Lung Cancer at ASCO

Fineline Cube Jun 3, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) presented the latest results from the...

Company Drug

Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting

Fineline Cube Jun 3, 2025

Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...

Company Drug

Innovent Biologics Presents IBI363 Clinical Results at 2025 ASCO Annual Meeting

Fineline Cube Jun 3, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the oral presentation of results from two clinical...

Company Drug

BeOne Medicines Wins Conditional Approval for Ziihera in HER2-Positive BTC

Fineline Cube Jun 3, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...

Posts pagination

1 … 177 178 179 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.